These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 21552299)

  • 1. Recombinant human soluble thrombomodulin for the treatment of hepatic sinusoidal obstructive syndrome post allogeneic hematopoietic SCT.
    Nakamura D; Yoshimitsu M; Kawada H; Inoue H; Kuroki T; Kaieda T; Fujino S; Hamada H; Suzuki S; Matsushita K; Uozumi K; Arima N
    Bone Marrow Transplant; 2012 Mar; 47(3):463-4. PubMed ID: 21552299
    [No Abstract]   [Full Text] [Related]  

  • 2. Successful treatment of sinusoidal obstructive syndrome after hematopoietic stem cell transplantation with recombinant human soluble thrombomodulin.
    Ikezoe T; Togitani K; Komatsu N; Isaka M; Yokoyama A
    Bone Marrow Transplant; 2010 Apr; 45(4):783-5. PubMed ID: 19718058
    [No Abstract]   [Full Text] [Related]  

  • 3. Successful treatment of hepatic sinusoidal obstructive syndrome after hematopoietic stem cell transplantation in a child using recombinant thrombomodulin.
    Yamamoto S; Yagawa A; Toyama D; Akiyama K; Hayashi M; Mabuchi M; Shimizu T; Ikeda H; Isoyama K
    Acta Haematol; 2013; 129(1):62-4. PubMed ID: 23147560
    [No Abstract]   [Full Text] [Related]  

  • 4. Sinusoidal obstructive syndrome prophylaxis with recombinant human soluble thrombomodulin is feasible in gemtuzumab ozogamicin-treated patients undergoing allogeneic hematopoietic cell transplantation.
    Yamamoto S; Matsuno R; Sugishita Y; Kaneko R; Okamoto N; Koganesawa M; Fujita S; Akiyama K; Toyama D; Isoyama K
    Bone Marrow Transplant; 2017 Jul; 52(7):1068-1070. PubMed ID: 28368378
    [No Abstract]   [Full Text] [Related]  

  • 5. Successful treatment with recombinant soluble thrombomodulin of two cases of sinusoidal obstructive syndrome/hepatic veno-occlusive disease after bone marrow transplantation.
    Ohwada C; Takeuchi M; Kawaguchi T; Tsukamoto S; Sakai S; Takeda Y; Abe D; Sakaida E; Shimizu N; Yokote K; Iseki T; Nakaseko C
    Am J Hematol; 2011 Oct; 86(10):886-8. PubMed ID: 21818767
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of recombinant human soluble thrombomodulin on clinical outcomes of patients with coagulopathy after hematopoietic stem cell transplantation.
    Ikezoe T; Takeuchi A; Chi S; Takaoka M; Anabuki K; Kim T; Sakai M; Taniguchi A; Togitani K; Yokoyama A
    Eur J Haematol; 2013 Nov; 91(5):442-7. PubMed ID: 23952647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatic sinusoidal obstruction syndrome following hematopoietic stem cell transplantation.
    Krimmel T; Williams LA
    Oncol Nurs Forum; 2008 Jan; 35(1):37-9. PubMed ID: 18192151
    [No Abstract]   [Full Text] [Related]  

  • 8. Heterogeneous response to recombinant thrombomodulin by grade of sinusoidal obstructive syndrome after pediatric stem cell transplantation.
    Inagaki J; Kurauchi K; Fukano R; Noguchi M; Okamura J
    Bone Marrow Transplant; 2016 Nov; 51(11):1543-1545. PubMed ID: 27376445
    [No Abstract]   [Full Text] [Related]  

  • 9. Successful treatment of disseminated intravascular coagulation in a child with acute myelogenous leukaemia using recombinant thrombomodulin.
    Ogawa E; Yagasaki H; Kato M; Shichino H; Chin M; Mugishima H
    Br J Haematol; 2010 Jun; 149(6):911-2. PubMed ID: 20346017
    [No Abstract]   [Full Text] [Related]  

  • 10. Advances in the diagnosis and treatment of disseminated intravascular coagulation in haematological malignancies.
    Ikezoe T
    Int J Hematol; 2021 Jan; 113(1):34-44. PubMed ID: 32902759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of Recombinant Human Soluble Thrombomodulin in Treating Disseminated Intravascular Coagulation Complicating Allogeneic Hematopoietic Stem Cell Transplantation.
    Inoue Y; Matsunawa M; Sano F; Miura I
    Acta Haematol; 2018; 140(2):121-127. PubMed ID: 30227394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Double treatment of severe hepatic veno-occlusive disease after allogeneic peripheral blood progenitor cell transplantation with recombinant tissue plasminogen activator.
    Söhngen D; Bauser U; Boogen C; Aul C; Frieling T; Germing U; Schneider P; Kobbe G; Heyll A
    Thromb Haemost; 1997 Oct; 78(4):1299-300. PubMed ID: 9365005
    [No Abstract]   [Full Text] [Related]  

  • 13. Hepatic veno-occlusive disease after tranexamic acid administration in patients undergoing allogeneic hematopoietic stem cell transplantation.
    Mori T; Aisa Y; Shimizu T; Yamazaki R; Mihara A; Yajima T; Hibi T; Ikeda Y; Okamoto S
    Am J Hematol; 2007 Sep; 82(9):838-9. PubMed ID: 17506069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful treatment of veno-occlusive disease with recombinant tissue plasminogen activator in a patient requiring peritoneal dialysis.
    Simpson DR; Browett PJ; Doak PB; Palmer SJ
    Bone Marrow Transplant; 1994 Oct; 14(4):635-6. PubMed ID: 7858540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Successful treatment with recombinant thrombomodulin for disseminated intravascular coagulation complicated with hemophagocytic syndrome].
    Yamazaki H; Kondo T; Tatsumi G; Kotani S; Arai Y; Shirakawa K; Kitano T; Hishizawa M; Kadowaki N; Takaori-Kondo A
    Rinsho Ketsueki; 2015 Mar; 56(3):312-6. PubMed ID: 25876785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcome after reduced-intensity conditioning allogeneic SCT for AML in first complete remission: comparison of two regimens.
    Cahu X; Mohty M; Faucher C; Chevalier P; Vey N; El-Cheikh J; Guillaume T; Furst S; Delaunay J; Ayari S; Moreau P; Gastaut JA; Harousseau JL; Blaise D
    Bone Marrow Transplant; 2008 Nov; 42(10):689-91. PubMed ID: 18679370
    [No Abstract]   [Full Text] [Related]  

  • 17. Graft-versus-host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy: results of the EVTAC trial.
    Platzbecker U; von Bonin M; Goekkurt E; Radke J; Binder M; Kiani A; Stoehlmacher J; Schetelig J; Thiede C; Ehninger G; Bornhäuser M
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):101-8. PubMed ID: 19135948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuroleptic malignant syndrome-induced massive coagulopathy treated by recombinant human soluble thrombomodulin.
    Hayashida K; Fujishima S; Nakaya N; Abe S; Shiroshita-Takeshita A; Hori S
    Am J Emerg Med; 2013 Mar; 31(3):636.e1-3. PubMed ID: 23218866
    [No Abstract]   [Full Text] [Related]  

  • 19. Prophylactic recombinant thrombomodulin treatment prevents hepatic sinusoidal obstruction syndrome in high-risk pediatric patients that undergo hematopoietic stem cell transplants.
    Yamamoto S; Toyama D; Sugishita Y; Kaneko R; Okamoto N; Koganesawa M; Fujita S; Akiyama K; Matsuno R; Isoyama K
    Pediatr Transplant; 2018 Nov; 22(7):e13269. PubMed ID: 30003636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Successful treatment of very severe late-onset sinusoidal obstruction syndrome with recombinant human soluble thrombomodulin, steroids, and control of intra-abdominal pressure].
    Hirakawa T; Tanaka T; Matsumi J; Takeda W; Kim SW; Inamoto Y; Ito A; Yamaguchi K; Ishimaru S; Kumamoto T; Arakawa A; Sugiyama M; Dan L; Shigematsu M; Sato T; Ogawa C; Fukuda T
    Rinsho Ketsueki; 2020; 61(7):734-739. PubMed ID: 32759558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.